MARKET

SONN

SONN

Sonnet BioTherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.460
+0.090
+3.80%
After Hours: 2.530 +0.07 +2.85% 19:54 09/25 EDT
OPEN
2.340
PREV CLOSE
2.370
HIGH
2.505
LOW
2.335
VOLUME
592.95K
TURNOVER
--
52 WEEK HIGH
54.60
52 WEEK LOW
2.230
MARKET CAP
33.56M
P/E (TTM)
-0.0712
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 1d ago
Sonnet Announces New Preclinical Data For SON-1010 (Interleukin 12-F(H)AB)
Positive SCID mouse data further support the preclinical safety and dosing profile of SON-1010 for oncology applications No evidence of cytokine storm was observed Company is on track to submit an IND in
Benzinga · 09/01 12:39
Mid-Afternoon Market Update: Crude Oil Rises 2%; Children's Place Shares Plunge On Wider-Than-Expected Q2 Loss
Toward the end of trading Tuesday, the Dow traded down 0.43% to 28185.70 while the NASDAQ rose 0.35% to 11,419.42. The S&P also rose, gaining 0.12% to 3,435.35.
Benzinga · 08/25 18:30
Mid-Day Market Update: Dow Tumbles 170 Points; Viveve Medical Shares Spike Higher
Midway through trading Tuesday, the Dow traded down 0.60% to 28,137.82 while the NASDAQ rose 0.21% to 11,403.25. The S&P also fell, dropping 0.03% to 3,430.26.
Benzinga · 08/25 16:00
Mid-Morning Market Update: Markets Mostly Lower; Hormel Foods Earnings Top Views
Following the market opening Tuesday, the Dow traded down 0.24% to 28240.82 while the NASDAQ rose 0.01% to 11378.17. However, the S&P fell 0.02% to 3431.91.
Benzinga · 08/25 15:59
iBio and Viveve Medical among healthcare gainers; Proteostasis Therapeutics among losers
Gainers: Viveve Medical (VIVE) +113%. Orchard Therapeutics (ORTX) +27%. iBio (IBIO) +16%. Idera Pharmaceuticals (IDRA) +15%. Cutera (CUTR) +14%.Losers: Sonnet BioTherapeutics (SONN) -21%. Cancer Genetics (CGIX) -17%. Liminal BioSciences (LMNL) -16%. Proteostasis Therapeutics (PTI) -15%. Lipocine
Seekingalpha · 08/25 15:06
Sonnet Bio secures $10.5M from exercise of series A warrants
Sonnet BioTherapeutics ([[SONN]] -14.1%) has announced that all 3,300,066 Series A Warrants have been exercised at $3.19/share, with gross proceeds of $10.5M."Warrant exercise by our institutional shareholders gives us a good
Seekingalpha · 08/25 13:36
DADA, VXRT among premarket losers
Cancer Genetics (CGIX) -16%.Smith & Wesson Brands (SWBI) -12% after American Outdoor Brands spin-off completed.Sonnet BioTherapeutics Holdings (SONN) -11%.Borqs Technologies (BRQS) -10%.Vaxart (VXRT) -9%.Kirkland's (KIRK) -8%.DHT Holdings (DHT) -8%.Dada Nexus (DADA) -7% on Q2
Seekingalpha · 08/25 12:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SONN. Analyze the recent business situations of Sonnet BioTherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SONN stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 504.50K
% Owned: 3.70%
Shares Outstanding: 13.64M
TypeInstitutionsShares
Increased
2
241.63K
New
10
7.33K
Decreased
1
165
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/President/Chief Executive Officer/Director
Pankaj Mohan
Chief Financial Officer/Treasurer/Secretary
John Cross
Corporate Executive
Richard Adams
Chief Operating Officer
Mark Roberson
Corporate Executive
Rich Adams
Chief Technology Officer
Susan Dexter
Chief Scientific Officer
John Cini
Other
Terence Rugg
Director
Nailesh Bhatt
Director
Albert Dyrness
Director
Donald Griffith
Director
Raghu Rao
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SONN
Sonnet Biotherapeutics Holdings Inc, formerly Chanticleer Holdings, Inc., an oncology-focused biotechnology company. The Company is developing targeted biologic drugs with enhanced single or bispecific mechanisms.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ:SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.